The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
The sellers never planned on owning the 30.7-acre property in Lyme, but bought it after a boat deal fell through. Now it’s ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...
Hosted on MSN13h
Earnings Preview: What to Expect From Gilead Sciences’ ReportSituated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...
HealthDay on MSN1h
2011 to 2022 Saw Increasing Prevalence of Poor Mental HealthPoor mental health was increasingly prevalent from 2011 to 2022, with inequities discernible by age, sex, and racial and ethnic group, according to a research letter published online Jan. 15 in JAMA ...
GlobalData on MSN13h
FDA beats EMA to most approved new drugs in 2024The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his ...
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of ...
In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...
The search is on for a suspect who Huntersville Police said shoved an elderly man and stole his vehicle at a local gas ...
Explore some of the best blue-chip ETFs to buy for investors who want to sleep well at night (SWAN) during their retirement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback